REGULAR VS AS-NEEDED INHALED SALBUTAMOL IN ASTHMA CONTROL

被引:77
作者
CHAPMAN, KR
KESTEN, S
SZALAI, JP
机构
[1] UNIV TORONTO,DIV RESP MED,TORONTO,ON,CANADA
[2] UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA
关键词
D O I
10.1016/S0140-6736(94)92520-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent studies have suggested that regular use of inhaled beta, agonists cause loss of asthma control as measured by worsening peak-flow rates, increased asthma symptoms, and more frequent need for supplementary bronchodilators. However, the magnitude of this effect and the reliability of investigator-originated definitions of control is unknown. We studied 341 people with asthma in a four-week, randomised, crossover trial of regular salbutamol (2 puffs-200 mu g-four times daily) for two weeks and as needed for two weeks. There were no significant differences in morning and evening peak-flow rates between treatments but asthma symptoms and supplementary bronchodilator use were significantly less frequent when salbutamol was given regularly. Asthma episodes occurred 1.39 (1.52) times per day during regular treatment and 2.44 (1.75) times per day during as-needed treatment (p<0.0001) and 0.50 (0.56) vs 0.65 (0.66) times per night (p < 0.0001). Daytime use of supplementary salbutamol was 1.14 (1.40) vs 2.35 (1.71) puffs per day, (p <0.0001); night-time use was 0.45 (0.55) vs 0.64 (0.66) puffs per night (p < 0.0001). When control endpoints were compared between treatment periods for each individual by two blinded investigators and control judged by six different sets of criteria, in 70 asthmatics there was no difference in symptom control between periods but in the remainder, control was achieved more often by regular than by as-needed salbutamol (166 vs 69, p < 0.0001). In asthma of moderate severity, regularly administered salbutamol does not produce lower peak flow rates than as-needed salbutamol and is associated with less frequent asthma symptoms.
引用
收藏
页码:1379 / 1382
页数:4
相关论文
共 20 条
[1]   REGULAR INHALED SALBUTAMOL AND AIRWAY RESPONSIVENESS TO ALLERGEN [J].
COCKCROFT, DW ;
MCPARLAND, CP ;
BRITTO, SA ;
SWYSTUN, VA ;
RUTHERFORD, BC .
LANCET, 1993, 342 (8875) :833-837
[2]  
CRANE J, 1989, LANCET, V1, P917
[3]  
JENNE JW, 1993, BRONCHIAL ASTHMA MEC, P700
[4]   EFFECT OF LONG-TERM TREATMENT WITH INHALED CORTICOSTEROIDS AND BETA-AGONISTS ON THE BRONCHIAL RESPONSIVENESS IN CHILDREN WITH ASTHMA [J].
KERREBIJN, KF ;
VANESSENZANDVLIET, EEM ;
NEIJENS, HJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1987, 79 (04) :653-659
[5]   A 3-MONTH COMPARISON OF TWICE DAILY INHALED FORMOTEROL VERSUS 4 TIMES DAILY INHALED ALBUTEROL IN THE MANAGEMENT OF STABLE ASTHMA [J].
KESTEN, S ;
CHAPMAN, KR ;
BRODER, I ;
CARTIER, A ;
HYLAND, RH ;
KNIGHT, A ;
MALO, JL ;
MAZZA, JA ;
MOOTE, DW ;
SMALL, P ;
TARLO, S ;
GONTOVNICK, L ;
REBUCK, AS .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03) :622-625
[6]   CHANGES IN BRONCHIAL HYPERREACTIVITY INDUCED BY 4 WEEKS OF TREATMENT WITH ANTIASTHMATIC DRUGS IN PATIENTS WITH ALLERGIC-ASTHMA - A COMPARISON BETWEEN BUDESONIDE AND TERBUTALINE [J].
KRAAN, J ;
KOETER, GH ;
VANDERMARK, TW ;
SLUITER, HJ ;
DEVRIES, K .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1985, 76 (04) :628-636
[7]   BETA-AGONISTS IN ASTHMA - STATE-OF-THE-ART - REPORT ON A ROYAL-SOCIETY-OF-MEDICINE SEMINAR [J].
KUITERT, LM .
THORAX, 1992, 47 (07) :568-569
[8]  
LOFDAHL CG, 1991, EUR RESPIR J, V4, P218
[9]   TOLERANCE TO THE NONBRONCHODILATOR EFFECTS OF INHALED BETA-2-AGONISTS IN ASTHMA [J].
OCONNOR, BJ ;
AIKMAN, SL ;
BARNES, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1204-1208
[10]   PROLONGED PROTECTION AGAINST METHACHOLINE-INDUCED BRONCHOCONSTRICTION BY THE INHALED BETA-2-AGONIST FORMOTEROL [J].
RAMSDALE, EH ;
OTIS, J ;
KLINE, PA ;
GONTOVNICK, LS ;
HARGREAVE, FE ;
OBYRNE, PM .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (05) :998-1001